If you’re planning a health outcomes study in Germany, choosing between statutory and commercial claims data isn’t about which dataset is bigger. The real question: does your research question even qualify for statutory access, and can your timeline afford to wait?
Key Takeaways
- The size of a dataset is only one factor in choosing a German health data source – the research question should always come first.
- FDZ Gesundheit provides pseudonymised statutory health insurance (SHI) data covering ~90% of the German population, but access is restricted to legally defined public-interest purposes and follows a structured application process.
- Commercial claims data providers offer faster project initiation, greater analytical flexibility, and ongoing access – advantages that matter greatly for iterative or market-access-focused research.
- The Gesundheitsdatennutzungsgesetz (GDNG), enacted in March 2024, is reshaping Germany’s health data landscape – and understanding what it does (and doesn’t) change is essential for planning ahead.
- MEDDDICAL’s overview of German health data providers and claims data under the GDNG maps out the full picture for health outcomes researchers working through these choices.
Germany’s statutory health insurance claims data ranks among the most detailed in Europe. But having access to rich data is not the same as having access to the right data – for the right project, at the right time. That distinction separates a well-designed study from one that stalls partway through.
The appropriate choice depends heavily on the research question. For example, rare disease research can place greater importance on population coverage, while HEOR and market access research may place greater emphasis on flexibility and project timelines.
The Dataset Size Trap Researchers Fall Into
When evaluating German health data sources, the instinct is to reach for the biggest number. If one dataset covers 74 million people and another covers a fraction of that, surely the larger one wins?
Not necessarily. Population size determines what’s possible – it doesn’t determine what’s appropriate. A nationwide dataset offers no meaningful advantage if the study question doesn’t require national representativeness. Chasing coverage at the expense of speed, flexibility, or legal eligibility can quietly derail an entire research program before it starts.
The real question is: what does this study actually need to answer its question? That reframe changes how to evaluate the available options in Germany.
What FDZ Gesundheit Actually Covers
The Health Data Lab – formally known as the FDZ Gesundheit – launched on October 9, 2025, and holds fully pseudonymised SHI claims data collected between 2009 and 2023. It is governed by the Gesundheitsdatennutzungsgesetz (GDNG), enacted in March 2024, which replaced fragmented bilateral data-sharing arrangements with a centralised, population-representative model administered through BfArM.
90% SHI Population, But Access Is Gated
The scale is genuinely impressive: approximately 90% of Germany’s population – around 74 million people – is represented in the statutory dataset. For studies on very rare diseases, national healthcare resource utilisation, or population-level epidemiology, that breadth can be scientifically decisive.
Access is not open, however. Researchers work within a secure virtual processing environment where data cannot be downloaded. Analytical outputs require formal clearance before export. Applications opened with the FDZ Gesundheit’s official launch on October 9, 2025, meaning lead times are real and must be planned for well in advance. The FDZ is also planning to integrate electronic patient records (ePA) from October 2026, which will further expand its research value over time.
Legally Permitted Purposes Only
FDZ Gesundheit access is explicitly reserved for public-interest research purposes – rare disease research, health system improvement, epidemiology, and similar objectives. Market access research and commercially focused projects fall outside the scope of what the GDNG permits. That boundary is a fundamental design feature of the system, not a loophole to work around. Researchers whose work falls into commercial categories need a different route.
Where Commercial Claims Data Has the Edge
Commercial health data providers in Germany – including InGef, INSIGHT Health, and IQVIA Germany – offer access to large longitudinal claims databases derived from voluntarily contributed SHI data, anonymised to GDPR standards. These databases don’t require the GDNG application process, which changes the operational calculus significantly for many research programs.
Speed and Iterative Flexibility
Project timelines are often underestimated as a selection criterion. Commercial providers support rapid project initiation, predictable delivery schedules, and the ability to refine study designs mid-stream without restarting a formal application. For health outcomes research that evolves – where new questions emerge from early findings – that flexibility is a core requirement.
IQVIA’s panel-based longitudinal prescription data (LRx), for example, covers approximately 80% of dispensed prescriptions in Germany, making it well-suited for treatment pattern analysis and commercial analytics. Commercial claims databases more broadly cover outpatient and inpatient care, demographics, prescriptions, and costs, though data availability typically carries a lag of at least one year.
When Nationwide Coverage Isn’t Necessary
Many well-powered studies don’t need 74 million lives. A large commercial database can provide sufficient statistical power for prevalence and incidence analyses, disease burden assessments, and healthcare resource utilisation studies – without the access timeline or legal eligibility constraints of the statutory route. The trade-off is that commercial panel designs may raise representativeness questions in regulatory-grade submissions, which is a consideration to weigh explicitly.
Five Questions That Point to the Right Source
Rather than defaulting to one data source or the other, the following questions help surface which path actually fits the project.
Does the Study Require National Representativeness?
National representativeness matters for studies on very rare diseases (where even large commercial panels may not yield sufficient cases), national-level HEOR analyses, or regulatory submissions where population coverage and data governance credibility are priorities. If the answer is yes – and the project qualifies under the GDNG’s permitted purposes – FDZ Gesundheit is likely the stronger fit. If national coverage isn’t scientifically necessary, a commercial source may be equally valid and operationally faster.
How Quickly Are Results Needed?
Statutory access involves formal applications, predefined research purposes, scheduled analytical environments, and controlled output release. Commercial providers can initiate projects far more quickly. If results are needed within months rather than years, that timeline reality should factor heavily into the decision – regardless of how attractive the statutory dataset’s population size might appear on paper.
Will the Study Design Evolve?
Iterative research – where the protocol adapts based on emerging findings – is difficult to execute within a structured statutory access model. Commercial providers accommodate repeated analyses, design refinements, and ongoing access for updates or future publications. For evidence-generation programs spanning multiple studies or years, that operational flexibility often outweighs the population-size advantage of the statutory route.
Two additional questions are worth asking: Does the project qualify for statutory access under the GDNG’s legal purposes? And are future data updates or publications anticipated? Both shape which access model will serve the research program across its full lifecycle.
The GDNG Is Reshaping Germany’s Data Landscape
The GDNG didn’t just create a new data portal – it formalised a new philosophy around health data access in Germany. By replacing ad hoc bilateral arrangements with a centralised, regulated framework, it has made statutory data access more systematic and more credible. Germany is also preparing for integration with the European Health Data Space (EHDS), which will open further cross-border research opportunities as that infrastructure matures.
What hasn’t changed is the underlying fragmentation challenge. Germany’s 16 federal states have historically complicated the rollout of national digital health infrastructure – from electronic health records to ePrescriptions. The GDNG addresses statutory data governance directly, but the broader data environment is still evolving.
Build a Strategy, Not a One-Time Choice
Many research organisations approach German health data as a one-time selection: pick a source, run the study, move on. A more durable approach treats statutory and commercial data as complementary tools rather than competing alternatives.
Exploratory analyses, commercial research, and time-sensitive deliverables may start with a commercial provider. Nationwide analyses with public-interest framing and sufficient lead time may route through FDZ Gesundheit. Follow-up studies can draw on insights from both environments. Building this kind of layered evidence strategy reduces administrative burden over time and positions organisations to generate higher-quality evidence across a range of projects.
Match the Question to the Data – Not the Other Way Around
The most important principle is a discipline, not a framework or a checklist. Start with the research question. Work backward to what the study needs: the required variables, the timeline, the governance requirements, the legal eligibility, the analytical flexibility. Then evaluate which data source actually delivers those things.
FDZ Gesundheit and commercial claims databases each occupy a distinct and legitimate role in Germany’s health research ecosystem. Neither is universally superior. The researchers who get the most out of Germany’s expanding data landscape are the ones who resist the dataset-size shortcut and instead match the question to the data – not the other way around.
The practical differences between these two approaches are discussed in more detail in our comparison of FDZ Gesundheit and commercial claims data providers.
MEDDDICAL helps health outcomes researchers work through Germany’s evolving health data environment – send us an email to discuss your objectives and benefit from our expert guidance.
